Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 369

1.

Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.

Asche CV, Hippler SE, Eurich DT.

Pharmacoeconomics. 2014 Jan;32(1):15-27. doi: 10.1007/s40273-013-0117-7. Review.

PMID:
24357160
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.
5.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
6.

Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.

Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.

Clin Drug Investig. 2016 Aug;36(8):649-59. doi: 10.1007/s40261-016-0410-2.

PMID:
27221806
7.

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.

BMC Health Serv Res. 2015 Nov 5;15:496. doi: 10.1186/s12913-015-1139-y.

8.

Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

Geng J, Yu H, Mao Y, Zhang P, Chen Y.

Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y. Review.

PMID:
25736235
10.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
11.
12.

Efficacy and safety of incretin based therapies: clinical trial data.

White J.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.

PMID:
19801363
13.

Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.

Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R.

Clin Ther. 2017 Jul;39(7):1347-1359. doi: 10.1016/j.clinthera.2017.05.354. Epub 2017 Jun 16.

PMID:
28625506
14.

Cost effectiveness of liraglutide in type II diabetes: a systematic review.

Zueger PM, Schultz NM, Lee TA.

Pharmacoeconomics. 2014 Nov;32(11):1079-91. doi: 10.1007/s40273-014-0192-4. Review.

PMID:
25052903
15.

Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.

Tricco AC, Antony J, Soobiah C, Hemmelgarn B, Moher D, Hutton B, Yu CH, Majumdar SR, Straus SE.

Syst Rev. 2013 Jun 28;2:47. doi: 10.1186/2046-4053-2-47.

16.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

17.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
18.

Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.

Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.

J Med Econ. 2014 Jul;17(7):499-507. doi: 10.3111/13696998.2014.912986. Epub 2014 Apr 23.

PMID:
24708176
19.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
20.

The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.

Smolen HJ, Murphy DR, Gahn JC, Yu X, Curtis BH.

J Manag Care Spec Pharm. 2014 Sep;20(9):968-84.

Supplemental Content

Support Center